Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Reviparin sodium

Known as: reviparin-sodium 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

reviparin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2004
Review
2004
Reviparin sodium clivarine: a review of its therapeutic use.
Reviparin sodium (clivarine) is a second generation LMWH, developed with the aim of maximising the antithrombotic action while… Expand
Highly Cited
2002
Highly Cited
2002
Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low-molecular-weight heparin with oral anticoagulant.
BACKGROUND Oral anticoagulants and low-molecular-weight heparin are both recommended for venous thromboembolism prophylaxis after… Expand
  • table 1
  • table 2
  • table 3
  • table 4
Highly Cited
2001
Highly Cited
2001
Prevention of venous thromboembolism after knee arthroscopy with low-molecular weight heparin (reviparin): Results of a randomized controlled trial.
PURPOSE Deep venous thrombosis (DVT) is a common, important complication of major orthopaedic surgery, particularly knee… Expand
2001
2001
Antithrombotic efficacy in a rat model of the low molecular weight heparin, reviparin sodium, administered by the oral route.
Previous studies in rats show that unfractionated heparin and the low molecular weight heparin logiparin have a dose-dependent… Expand
Review
2001
Review
2001
Reviparin: a review of its efficacy in the prevention and treatment of venous thromboembolism.
UNLABELLED Reviparin (reviparin sodium) is a low molecular weight heparin (LMWH) that catalyses the inactivation of factors Xa… Expand
  • figure 1
  • table I
  • table II
  • table III
  • table IV
Highly Cited
1997
Highly Cited
1997
Low-molecular-weight heparin in the treatment of patients with venous thromboembolism.
BACKGROUND Low-molecular-weight heparin is known to be safe and effective for the initial treatment of patients with proximal… Expand
1997
1997
[Prevention of thromboembolism in minimal invasive interventions and brief inpatient treatment. Results of a multicenter, prospective, randomized, controlled study with a low molecular weight heparin…
A prospective, randomised, controlled clinical trial was carried out in order to elucidate the incidence of venous… Expand
1997
1997
Thromboembolieprophylaxe bei minimal-invasiven Eingriffen und kurzstationärer Behandlung Ergebnisse einer multicentrischen, prospektiven, randomisierten, kontrollierten Studie mit einem…
Summary. A prospective, randomised, controlled clinical trial was carried out in order to elucidate the incidence of venous… Expand
Highly Cited
1996
Highly Cited
1996
Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial…
Resuhs. Using the intention to treat analysis for all patients. 102 (33.3%) in tbe reviparin group and 98 (32%) in the control… Expand
  • table 3
Review
1996
Review
1996
Cost-effectiveness of the low molecular weight heparin reviparin sodium in thromboprophylaxis.
  • V. Kakkar
  • Thrombosis research
  • 1996
    • Corpus ID: 32105616
Use of low molecular weight heparins (LMWHs) is now generally accepted as an ideal method of prophylaxis against postoperative… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE